30 related articles for article (PubMed ID: 12545813)
1. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in thyroid tumor progression: association with p53 gene mutations.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Jpn J Cancer Res; 1993 May; 84(5):526-31. PubMed ID: 8100564
[TBL] [Abstract][Full Text] [Related]
4. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400
[TBL] [Abstract][Full Text] [Related]
5. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas.
Shi Y; Zou M; Farid NR; al-Sedairy ST
Br J Cancer; 1996 Nov; 74(9):1336-41. PubMed ID: 8912526
[TBL] [Abstract][Full Text] [Related]
6. [Relationship of p53 gene mutation with pathological characteristics and prognosis of thyroid carcinoma].
Song Y; Wang L; Huang G; Yuan S; Xiao L
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):298-9, 314. PubMed ID: 12545813
[TBL] [Abstract][Full Text] [Related]
7. [Unique association of p53 mutations with undifferentiated carcinoma of the thyroid].
Ito T; Seyama T; Hayashi Y; Dohi K; Akiyama M
Nihon Rinsho; 1994 Apr; 52(4):1069-74. PubMed ID: 8196165
[TBL] [Abstract][Full Text] [Related]
8. [Genetic abnormality in thyroid cancers].
Yamashita S
Nihon Rinsho; 2005 Oct; 63 Suppl 10():159-62. PubMed ID: 16279621
[No Abstract] [Full Text] [Related]
9. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of mutations in thyroid tumors with TGGE.
Simon D; Goretzki PE; Schäfer C; Gorelov V; Ebeling B; Röher HD
Exp Clin Endocrinol Diabetes; 1995; 103(5):275-9. PubMed ID: 8536054
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
[TBL] [Abstract][Full Text] [Related]
12. Genetic considerations in thyroid cancer.
Patel KN; Singh B
Cancer Control; 2006 Apr; 13(2):111-8. PubMed ID: 16735985
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
